Hangzhou-based biopharmaceutical company VyBio is emerging as one of China’s most promising drug developers, focused on first-in-class and best-in-class innovative medicines with global intellectual property rights.
Founded in 2021, the company is building a strong international presence through its research in oncology and chronic disease therapeutics, with several candidates already in Phase I and Phase II clinical trials.
VyBio brings together a world-class team of scientists and executives educated at institutions including Tsinghua University, the University of California Los Angeles, the State University of New York, Sichuan University’s West China School of Medicine, and the University of Hong Kong.
The company’s founder and president, Dr. Sha Wei, previously served as general manager of TaiFeng Research Institute under TaiFeng Pharmaceutical Group, one of VyBio’s founding shareholders. Her extensive background spans the full drug development cycle—from early-stage research to commercialization—laying a solid foundation for VyBio’s rapid growth and translational capabilities.
VyBio’s co-founder and chairman, Dr. Ding Zhaozhong, brings over 30 years of experience in drug R&D and management, offering critical guidance across the company’s development programs. Meanwhile, Chief Scientific Officer Dr. Fang Dong contributes more than two decades of expertise in drug discovery and development.
Dr. Fang has participated in the creation of multiple marketed oncology therapies, including Lisaftoclax, Olverembatinib, Iruplinalkib, and Glasdegib, and has driven dozens of investigational new drug (IND) filings in both China and the United States. He has published over 40 peer-reviewed papers and holds more than 20 patents.
Backed by this seasoned leadership team, VyBio has made significant strides in developing new drugs targeting hypertension and a variety of solid tumors. Its clinical-stage portfolio includes VB19055, a highly selective aldosterone synthase inhibitor, and small-molecule oncology candidates TFX05, TFX06, and VB15. The company’s preclinical pipeline spans small-molecule and oligonucleotide therapies for cancer, hypertension, hyperlipidemia, and diabetes.
VyBio’s commitment to pioneering science and international standards has earned it numerous accolades, including recognition as a National High-Tech Enterprise, a National Technology-Based SME, and a Zhejiang Provincial Innovative Enterprise. In 2024, it was also selected as a Talent-Driven Demonstration Company and part of Hangzhou’s “Dayun Talent” entrepreneurship program.
“Our mission has always been to address unmet clinical needs through differentiated innovation,” said Dr. Ding. “Since inception, VyBio has adhered to an ‘In China, For Global’ R&D philosophy—developing globally competitive drugs from the ground up. Our small-molecule and oligonucleotide technology platforms form the backbone of our oncology and chronic disease pipelines.”
Dr. Ding added that the company’s latest financing has positioned VyBio for its next phase of growth: advancing its oncology assets into registration-enabling trials and pushing chronic disease candidates through clinical validation. “This marks a new chapter of acceleration toward commercialization,” he said. “Our goal is to create value for investors and deliver tangible health benefits to patients worldwide.”
Dr. Chen Kan, Partner and Co-Head of Healthcare Innovation at Qiming Venture Partners, a backer of VyBio, praised the company’s scientific rigor and innovation-driven approach. “VyBio stands out for its forward-looking target discovery and efficient compound optimization capabilities,” Chen said.
“The company has developed a portfolio of highly active, selective, and safe drug candidates with strong differentiation potential. With VyBio’s robust clinical development engine, these assets are well positioned to progress rapidly to market and unlock their full clinical and commercial value.”
